$XBI $131.42 -5%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$AKBA -5% Approval of Riona for additional indication in Japan. source
$RDUS +10% Updates for abaloparatide. source
$DVAX -6% First patient dosed in ph 2/3 covid trial. source
$PRQR +13% Ph 1/2 data from STELLAR trial of QR-421a. source
$MYOV -6% & $PFE Ph 3 data from LIBERTY study for uterine fibroids. source
$HCM -4% Initiated ph 1b/2 trial of surafitinib + tislelizumab in solid tumors. source
Financial Updates
$EVFM -10% Public offering. source
$AVEO -8% Prices offering at $8/sh. source
Comments